Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01544998 · ClinicalTrials.gov registry record · Phase 1
Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01544998: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01544998 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 43 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01544998, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is being done to determine the effects of subcutaneous (under the skin) injection of human B-type natriuretic factor (BNP), Natrecor (nesiritide), a hormone produced by the heart, in combination with Tadalafil on: * The pumping function of the heart * Kidney function * Hormonal function (levels of different hormones in your blood) in persons with lower pumping function of their heart.
Primary Outcome
Value at 60 minutes minus value at baseline.
Interventions
- DRUG Placebo
- DRUG Tadalafil
- DRUG Nesiritide
- DRUG Saline load
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
What the finished NCT01544998 record still lists
NCT01544998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01544998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01544998 about?
NCT01544998 is a clinical study titled "Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure". This study is being done to determine the effects of subcutaneous (under the skin) injection of human B-type natriuretic factor (BNP), Natrecor (nesiritide), a hormone produced by the heart, in combination with Tadalafil on: * The pumping function of the heart * Kidney function * Hormonal function ...
What is the current status of trial NCT01544998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2012-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01544998?
The interventions under investigation include: Placebo (DRUG), Tadalafil (DRUG), Nesiritide (DRUG), Saline load (DRUG).
Who is sponsoring clinical trial NCT01544998?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01544998's enrollment target sits among peer trials
43 1100th of 2000 higher than 896 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia